ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations
PD-1-Naïve Patients More Likely To Derive Benefit
Clinical data released on drugs targeting LAG-3 from BMS, Regeneron, Merck & Co. and Immutep in a variety of cancers.
You may also be interested in...
Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.
The LAG-3 antibody relatlimab, with Opdivo in the fixed-dose combo Opdualag and a $27,389-per-dose price, is the first approved in a new class of checkpoint inhibitors since the anti-PD-1/PD-L1s.
Keeping Track: US FDA Is Approving JAK Inhibitors Again, Starting With Incyte’s Opzelura; Seagen’s Tivdak Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.